|
Neonatal Intensive Care Drug Manual
|
| bet | 575/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Spironolactone
Revision Date : 18/2/2021
|
Approved: TC, KOH
|
Alert
|
Spironolactone is a potassium-sparing diuretic and concomitant intake of potassium or ACE inhibitors may lead to hyperkalemia.
|
Indication
|
Diuretic primarily prescribed for its potassium-sparing effect.
For heart failure, in conjunction with furosemide.
For chronic lung disease, in conjunction with a thiazide diuretic.
Bartter syndrome and Gitelman Syndrome.
|
Action
|
Spironolactone is a synthetic steroid that acts as a competitive aldosterone receptor antagonist, so inhibits sodium reabsorption and spares potassium. It is a weak diuretic.
It also inhibits the interaction between dihydrotestosterone and the intracellular androgen receptor resulting in moderate antiandrogenic activity..
|
Drug type
|
Non-selective mineralocorticoid receptor antagonist.
|
|
|
| |
